We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

    • Adeno-associated virus

    Health

    AAVantgarde Bio to Present Pioneering Gene Therapy Findings at FLORetina Annual Meeting

    AAVantgarde Bio, a leading biotechnology firm in Italy, will present groundbreaking findings from its LUCE-1 clinical study at the FLORetina Annual Meeting on December 7, 2024. The study focuses on a novel dual AAV gene therapy for treating advanced retinitis pigmentosa due to Usher syndrome 1B, marking a significant advancement in ophthalmology. Prof. Francesca Simonelli will discuss the safety results from initial subjects, highlighting the potential of innovative gene therapies in inherited retinal disease treatment.

    Posted on Jhon
    Health

    Novel Gene Therapy Vehicle Successfully Crosses Blood-Brain Barrier in Mice

    Researchers at the Broad Institute have developed a groundbreaking gene therapy delivery vehicle that effectively crosses the blood-brain barrier in mice, offering new possibilities for treating a range of brain diseases. This innovative approach utilizes a human protein to transport therapeutic genes into the brain, promising safer and more efficient treatments for neurodevelopmental and neurodegenerative disorders.

    Posted on Jhon
    Health

    Scientists Conduct First-Ever Gene Therapy Tests in Whole Human Liver

    Groundbreaking study by Children’s Medical Research Institute (CMRI) conducts first-ever gene therapy tests in whole human liver, aiming to develop more effective treatments for inherited diseases. Research addresses challenges in bringing gene therapies from lab to clinic, utilizing innovative normothermic liver perfusion system to test AAV-based therapeutics before clinical studies. Senior author expresses excitement about potential for directly assessing gene therapeutics in human liver.

    Posted on Jhon